Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741919 | 0.75 | CHRM3 (0.30) | — | |
| Iodide SCHEMBL7846998 | 0.69 | — | — | |
| SCHEMBL30752302 | 0.66 | — | — | |
| SCHEMBL11518996 | 0.62 | — | — | |
| SCHEMBL8023877 | 0.62 | — | — | |
| SCHEMBL12494103 | 0.59 | — | — | |
| SCHEMBL8844169 | 0.58 | HRH3 (0.32) | — | |
| SCHEMBL11751363 | 0.55 | LMNA (0.37) | — | |
| SCHEMBL23037243 | 0.55 | PBRM1 (0.57) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31179821 | 0.55 | PBRM1 (0.57) | SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019074492-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2019-04-18 | — | — | WO | claimed |
| EP-3394057-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | Neurocrine Biosciences Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| WO-2018140093-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2018140092-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2018140096-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2018140095-A2 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2018140094-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | OBRIEN CHRISTOPHER F (US) | 2018-08-02 | — | — | WO | claimed |
| WO-2017112857-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| EP-3102239-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-12-14 | — | — | EP | claimed |
| WO-2015120317-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-08-13 | — | — | WO | claimed |
| EP-3836926-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | Neurocrine Biosciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020227672-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3706748-A1 | ESTERS OF DIHYDROTETRABENAZINE | Foresee Pharmaceuticals Co., Ltd. (CN) | 2020-09-16 | — | — | EP | disclosed |
| WO-2020037022-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3548027-A1 | USE OF VALBENAZINE FOR TREATING SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER | NEUROCRINE BIOSCIENCES, INC. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2015048370-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| EP-2217599-A1 | ALPHA-FLUOROALKYL TETRABENAZINE AND DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | General Electric Company (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2081929-A1 | SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDOÝ2,1-A¨ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009070552-A1 | ALPHA-FLUOROALKYL TETRABENAZINE AND DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008058261-A1 | SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-05-15 | — | — | WO | disclosed |